Successful Treatment of Invasive Squamous Cell Carcinoma Using Topical Imiquimod

Hengge, Ulrich R.; Schaller, Jörg

doi:10.1001/archderm.140.4.404

Cited by 35 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Topical imiquimod has also been used in a variety of different skin disorders including nodular and superficial BCC (29), in situ and invasive SCC (30)(31), lentigo maligna (32), lentigo maligna melanoma (33), keratoacanthomas (34), primary cutaneous CD30 positive anaplastic large cell lymphoma (35), mycosis fungoides (36), extramammary Paget's disease (37), cutaneous melanoma metastases (38), cutaneous warts and molluscum contagiosum (39), stucco keratosis (40), cutaneous leishmaniasis (41) and keloids (42).…”

Section: Imiquimod: a Promising Topical Immunostimulatory Agent For Dmentioning

confidence: 99%

Efforts to Counteract Locally the Effects of Systemic Immunosupression: A Review on the Use of Imiquimod, a Topical Immunostimulator in Organ Transplant Recipients

Trakatelli

Katsanos

Ulrich

et al. 2010

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

The potent systemic immunosuppression therapy necessary to sustain a life-saving solid organ transplant is associated with an increased incidence of various infections including human papillomavirus infection and skin cancers in organ transplant recipients. Imiquimod, a topical agent that functions through local induction of a specific anti-viral or anti-tumor immune response, appears to be a promising therapeutic option that could potentially counteract in situ the effects of systemic immunosupression in this vulnerable group. Up-to-date studies using this local immune-response modifier in transplanted patients have yielded reassuring and encouraging results regarding its safety and efficacy in this population. However, in order to establish the use of imiquimod as a standard treatment option for organ transplant recipients, additional research and clinical trials are required.The past decades have seen unprecedented progress in the development of solid organ transplantation as a therapeutic choice for endstage organ disease. Organ Transplant Recipients (OTR) live longer, have a good quality of life and represent a rapidly growing population of people with specific medical needs. As the number of solid organ transplants continues to rise, so too does the number of various infections including human papillomavirus (HPV) infections and skin cancers in OTR. Consequently, physicians will be called upon to manage these diseases in the sensitive OTR population and to develop novel therapeutic and preventive strategies to better deal with them.The clinical efficacy of imiquimod 5% cream (a topical therapy approved for genital warts, actinic keratoses and superficial basal cell carcinoma) stems from stimulation ofinnate and cell-mediated immune responses, resulting in antiviral, antiproliferative and antitumor activity. Because of these properties, imiquimod and other members of this family of immune response modifiers are potential agents for treatment of conditions where the immune system can affect the regression of the disease (1). In light of the role of systemic immunosupression in the development of cutaneous infections and neoplasms in OTR, the use of imiquimod to locally stimulate immune responses against cancerous, pre-cancerous

show abstract

Section: Imiquimod: a Promising Topical Immunostimulatory Agent For Dmentioning

confidence: 99%

Efforts to Counteract Locally the Effects of Systemic Immunosupression: A Review on the Use of Imiquimod, a Topical Immunostimulator in Organ Transplant Recipients

Trakatelli

Katsanos

Ulrich

et al. 2010

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…74 Case reports suggest that imiquimod can also be useful in treating invasive SCC. 76,77 Adverse effects of 5FU include erythema, pain, dermatitis, and pruritus and resulted in treatment discontinuation in 5% of patients, whereas approximately 3% discontinued imiquimod treatment due to erythema, edema, weeping, pruritus, hypopigmentation, erosion, burning, and pain. 75 Given that 5-year cure rates for 5FU and imiquimod remain unknown, neither can be recommended in SCC.…”

Section: Topical Regimensmentioning

confidence: 99%

Non-melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma

et al. 2015

View full text Add to dashboard Cite

Background Squamous cell carcinoma (SCC) is the second-most common form of non-melanoma skin cancer (NMSC). Objective To provide guidance to Canadian health care practitioners regarding management of SCCs. Methods Literature searches and development of graded recommendations were carried out as discussed in the accompanying introduction (chapter 1 of the NMSC guidelines). Results SCCs are sometimes confined to the epidermis, but they can also invade nearby tissues and, in some cases, metastasize to neighbouring lymph nodes or other organs. This chapter discusses the natural history, staging, prognosis, and management of SCC—a tumour type that is less common but typically more aggressive than BCC. For this reason, margin control is strongly preferred in treating SCCs. Conclusions Although approaches such as cryosurgery and radiation therapy may be considered for some patients, surgical excision—sometimes coupled with radiation—remains the cornerstone of SCC management. Patients with high-risk SCC may also be considered for referral to an appropriate multidisciplinary clinic.

show abstract

“…Imiquimod 5%, a topical immunomodulating agent that stimulates cytokine production, has been effective in treating localized, superficial BCC [25••]. A few case reports have suggested that imiquimod may be effective in the treatment of Bowen's disease and invasive SCC [26,27]. Although these therapies are not appropriate for the current treatment of high-risk NMSC, they may be combined with conventional modalities in the future.…”

Section: Chemotherapy and Chemopreventionmentioning

confidence: 99%

High-risk non-melanoma skin cancer of the head and neck

Lai¹,

Weber²

2005

Curr Oncol Rep

View full text Add to dashboard Cite

High-risk non-melanoma skin cancer (NMSC) of the head and neck is difficult to manage, given its propensity for regional metastasis, perineural invasion, direct parotid invasion, and bony destruction. Management of these tumors demands awareness of the characteristics contributing to their recurrence. Recent studies emphasize the importance of treatment of the parotid gland and cervical lymph nodes to improve locoregional control. A multidisciplinary approach to the assessment and treatment of high-risk NMSC is required to provide comprehensive care. This review also covers recent advances in the understanding of NMSC biology and new approaches in chemoprevention.

show abstract

Successful Treatment of Invasive Squamous Cell Carcinoma Using Topical Imiquimod

Cited by 35 publications

References 17 publications

Efforts to Counteract Locally the Effects of Systemic Immunosupression: A Review on the Use of Imiquimod, a Topical Immunostimulator in Organ Transplant Recipients

Efforts to Counteract Locally the Effects of Systemic Immunosupression: A Review on the Use of Imiquimod, a Topical Immunostimulator in Organ Transplant Recipients

Non-melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma

High-risk non-melanoma skin cancer of the head and neck

Contact Info

Product

Resources

About